Results from a clinical study of DJO's EMPOWR 3D Knee indicate that the technology reduces patient dissatisfaction while improving function and activity levels.
Regentis Biomaterials expanded the SAGE clinical trial of GelrinC to 11 U.S. sites. The investigational device is in evaluation to regrow knee cartilage.
SI-BONE closed its previously-announced initial public offering of 8,280,000 shares of common stock, priced at US $15 per share. The company is now trading on Nasdaq with the ticker symbol SIBN.